A phase II trial of adjuvant bevacizumab and erlotinib in patients at high risk for early relapse following radical prostatectomy for prostate cancer
Phase of Trial: Phase II
Latest Information Update: 29 Mar 2016
At a glance
- Drugs Bevacizumab (Primary) ; Erlotinib (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 17 Feb 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 19 Dec 2005 New trial record.